Although patients with MDS and AML shared common gross structural aberrations and intragenic TP53 aberrations (Figure 1), there was substantial diversity in each patient's allelic state, response to front‐line therapy, HCT candidacy, and ultimately clinical outcomes. This evidence concerns the gene TP53 and myelodysplastic syndrome.